In recent years there has been a proliferation of psychiatric disorders. The pharmaceutical industry in cahoots with the psychiatric industry has for a long time been on the trail of inventing new diseases to throw their drugs at and, if a pill stays on the shelf for too long, they find new illnesses to throw it at. Normal human responses and conditions are, according to this money-hungry machine, very serious illnesses and disorders which can only be treated with mountainloads of drugs.
Shy people have Social Anxiety Disorder, nervous people have GAD, kids who are just being kids have ADHD and women with PMT are all of a sudden plagued with the incurable (but according to Eli Lilly eminently treatable with repackaged Prozac as Sarafem) PMDD or Pre-Menstrual Dysphoric Disorder (See: Old drug for a 'new' female disorder).
And what about Panic Disorder? Is it really a true psychiatric condition? I'm very uneasy about this label since it was a term concocted by Upjohn/Pharmacia (now owned by Pfizer) to promote their drug Xanax. Like many other disease-mongering drugs companies they "bought" psychiatrists to write it up and persuade the FDA to approve it, but the majority of people I have spoken to these last few years suffer from panic as an iatrogenic condition. Anxiety isn't a disease but drugs companies aided and abetted by their legal pushers have turned it in to one. Benzodiazepines (all of them) cause, exacerbate and prolong the symptoms of anxiety and beguile the user into believing that these drugs are of benefit. It's an awful trap to be caught in but millions unwittingly buy into the lie.
"Panic Disorder is an 'illness' specifically invented to market Xanax/alprazolam. This is described by Dr David Healy in his book "The Psychopharmacologists". Also I agree that panic attacks are often iatrogenic or drug-induced. The ones I hear of are often people coming off benzos, starting antidepressants (especially SSRIs) or as a result of cannabis," according to Professor Heather Ashton.
"Healy points out that drug companies "are now not simply confined to finding drugs for diseases. They have the power to all but find diseases to suit the drugs they have". ... One of many examples of this process was the development in the 1970s of alprazolam (Xanax) for panic disorder. According to David Sheehan (Institute for Research and Psychiatry, Tampa, Florida), the marketing of this drug involved a "clear strategy" to take advantage of the medical profession's confusion in the classification of anxiety disorders; "to create a perception that the drug had special and unique properties that would help it capture market share and displace diazepam from the top position... There was in fact nothing unique in this regard about Xanax... benzodiazepines were all good for panic disorder." Xanax was marketed by Upjohn with F.D.A. approval of doses up to 6mg daily (equivalent to 60-120mg diazepam). It is perhaps no coincidence, as Healy observes, that the effective incidence of panic disorders has grown 1000-fold since 1980." - Professor Heather Ashton, DM, FRCP, A View from the Shoulders of Giants, A Review of David Healy's "The Psychopharmacologists III", September, 2001.
What do you make of Explosive Brain Disorder? Note that this relies so heavily on the "chemical imbalance in the brain" hocus-pocus. Do they really expect us to fall for these scams? This merry-go-round seems unstoppable. The drugs companies have whole truckloads of drugs to sell and they're always coming up with new "diseases" to throw them at aided and abetted by the legions of willing doctors. Are these people really concerned about your health and well-being or do they just wish to drug you from the cradle to the grave and carry your cash to the bank? Do governments perhaps have a vested interest in keeping you sick, drugged, dependent and docile?
First, you market the disease... then you push the pills to treat it
First, you market the disease... then you push the pills to treat it
Brendan I Koerner on the ugly truth about doctors, PR firms and drug companies
Tuesday July 30, 2002
The Guardian
Word of the hidden epidemic began spreading in spring last year. Local news reports around the United States reported that as many as 10 million Americans suffered from an unrecognised disease. Viewers were urged to watch for the symptoms: restlessness, fatigue, irritability, muscle tension, nausea, diarrhoea, and sweating, among others. Many of the segments featured soundbites from Sonja Burkett, a patient who had finally received treatment after two years trapped at home by the illness, and from Dr Jack Gorman, an esteemed psychiatrist at Columbia University.
The disease was generalised anxiety disorder (GAD), a condition that, according to the reports, left sufferers paralysed with irrational fears. Mental-health advocates called it "the forgotten illness". Print periodicals were awash with stories of young women plagued by worries over money and men. "Everything took 10 times more effort for me than it did for anyone else," one woman told the Chicago Tribune. "The thing about Gad is that worry can be a full-time job. So if you add that up with what I was doing, which was being a full-time achiever, I was exhausted, constantly exhausted."
The timing of the media frenzy was no accident. On April 16 2001, the US food and drug administration (FDA) had approved the antidepressant Paxil, made by British pharmaceutical giant GlaxoSmithKline, for the treatment of Gad. But it was a little-known ailment; according to a 1989 study, as few as 1.2% of the US population merited the diagnosis in any given year. If GlaxoSmithKline hoped to capitalise on Paxil's newapproval, it would have to raise Gad's profile.
That meant revving up the company's public-relations machinery. The widely featured quotes from Burkett were part of a "video news release" the drug maker had distributed to TV stations around the country; the footage also included the comments of Gorman, who has frequently served as a paid consultant to GlaxoSmithKline. On April 16 - the date of Paxil's approval - a patient group called freedom from fear released a telephone survey which revealed that "people with Gad spend nearly 40 hours per week, or a 'full-time job,' worrying". The survey mentioned neither GlaxoSmithKline nor Paxil, but the press contact listed was an account executive at Cohn & Wolfe, the drugmaker's PR firm.
The modus operandi of GlaxoSmithKline - marketing a disease rather than selling a drug - is typical of the post-Prozac era. "The strategy [companies] use - it's almost mechanised by now," says Dr Loren Mosher, a San Diego psychiatrist and former official at the national institute of mental health. Typically, a corporate-sponsored "disease awareness" campaign focuses on a mild psychiatric condition with a large pool of potential sufferers. Companies fund studies that prove the drug's efficacy in treating the afiction, a necessary step in obtaining FDA approval for a new use, or "indication". Prominent doctors are enlisted to publicly affirm the malady's ubiquity, then public-relations firms launch campaigns to promote the new disease, using dramatic statistics from corporate-sponsored studies. Finally, patient groups are recruited to serve as the "public face" for the condition, supplying quotes and compelling stories for the media; many of the groups are heavily subsidised by drugmakers, and some operate directly out of the offices of drug companies' PR firms.
continues...